Her2/neu

  • Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
    Luca Zammataro, Salvatore Lopez, Stefania Bellone, Francesca Pettinella, Elena Bonazzoli, Emanuele Perrone, Siming Zhao, Gulden Menderes, Gary Altwerger, Chanhee Han, Burak Zeybek, Anna Bianchi, Aranzazu Manzano, Paola Manara, Emiliano Cocco, Natalia Buza, Pei Hui, Serena Wong, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Franco Odicino, Sergio Pecorelli, Carla Donzelli, Laura Ardighieri, Roberto Angioli, Francesco Raspagliesi, Giovanni Scambia, Jungmin Choi, Weilai Dong, Kaya Bilguvar, Ludmil B. Alexandrov, Dan-Arin Silasi, Gloria S. Huang, Elena Ratner, Masoud Azodi, Peter E. Schwartz, Valentina Pirazzoli, Amy L. Stiegler, Titus J. Boggon, Richard P. Lifton, Joseph Schlessinger, and Alessandro D. Santin
  • Bisphosphonates inactivate human EGFRs to exert antitumor actions
    Tony Yuen, Agnes Stachnik, Jameel Iqbal, Miriam Sgobba, Yogesh Gupta, Ping Lu, Graziana Colaianni, Yaoting Ji, Ling-Ling Zhu, Se-Min Kim, Jianhua Li, Peng Liu, Sudeh Izadmehr, Jaya Sangodkar, Jack Bailey, Yathin Latif, Shiraz Mujtaba, Solomon Epstein, Terry F. Davies, Zhuan Bian, Alberta Zallone, Aneel K. Aggarwal, Shozeb Haider, Maria I. New, Li Sun, Goutham Narla, and Mone Zaidi

    See companion article: